2023.02.08
On February 3, 2023, Structure Therapeutics Inc. (“Structure” or the “Company”) successfully listed and traded shares on the NASDAQ Stock Exchange with the stock code GPCR. Structure issued a total of 12,351,000 American Depositary Shares (ADSs) at a price of USD 15 per share, raising approximately USD 185.3 million. Structure’s IPO is an important sign of Chinese biotech companies’ restarting their IPOs on the NASDAQ.
As a clinical-stage biopharmaceutical company, Structure is committed to converting biologic and peptide drugs into oral small-molecule drugs with excellent efficacy. Structure has designed differentiated treatments focused on chronic diseases including cardiovascular, metabolic and pulmonary conditions, and overcome the limitations of biologics and peptide therapies targeting GPCR families.
JunHe acted as the domestic legal counsel to the underwriter in this project. JunHe’s team assisted the underwriter in carrying out domestic legal due diligence, reviewed and revised the application and offering documents relating to the IPO, responded to domestic legal concerns raised by the SEC, and issued Chinese legal opinions. Structure ultimately debuted successfully on the NASDAQ Stock Exchange. JunHe won the unanimous recognition and high trust from the Company, the underwriter and other intermediaries for its efficient and rigorous working style as well as its meticulous and dedicated attitude.
This project was led by partners YE, Yurong and CHEN, Yan. It was primarily undertaken by CHEN, Yan and WAN, Shang, and internally reviewed by partner LI, Zhi.
